2025 年 04 月 28 日 投资评级：买入（维持） 医药生物/化学制药 奥锐特（605116.SH） | 日期 | 2025/4/25 | | --- | --- | | 当前股价(元) | 21.30 | | 一年最高最低(元) | 26.99/18.70 | | 总市值(亿元) | 86.52 | | 流通市值(亿元) | 84.67 | | 总股本(亿股) | 4.06 | | 流通股本(亿股) | 3.98 | | 近 3 个月换手率(%) | 33.16 | 股价走势图 -36% -24% -12% 0% 12% 24% 2024-04 2024-08 2024-12 奥锐特 沪深300 数据来源：聚源 相关研究报告 《2024 前三季度业绩高速增长，制剂 业务快速放量—公司信息更新报告》 -2024.10.25 《2024 上半年业绩高速增长，制剂业 务快速放量—公司信息更新报告》 -2024.8.29 《难仿原料药持续拓展，制剂业务有 望成为新增长极—公司首次覆盖报 告》-2024.6.25 2025Q1 业绩高速增长，制剂业务快速放量 ——公司信息更新报告 | 余汝意（分析师） | 阮帅 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and business performance [1][2]. Core Insights - The company achieved a revenue of 425 million yuan in 2024, representing a year-over-year increase of 24.57%, with a net profit of 102 million yuan, up 13.10% year-over-year [1][2]. - The reproductive rehabilitation segment showed exceptional growth, with revenue reaching 110 million yuan in 2024, a significant increase of 126.56% year-over-year, driven by product upgrades and market expansion [2]. - The company is focusing on new product promotions, which may temporarily pressure gross margins, but the diverse product pipeline is expected to drive future growth [2]. Financial Summary - Total revenue for 2024 was 425 million yuan, with a projected growth rate of 17.0% for 2025, reaching 497 million yuan [3]. - The gross margin for the main business in 2024 was 72.25%, a decrease of 2.40 percentage points year-over-year [2]. - The company forecasts net profits of 136 million yuan in 2025, reflecting a year-over-year growth of 33.4% [3]. Business Performance - The company has strengthened its competitive position in the pelvic rehabilitation field, achieving revenue of 167 million yuan in this segment, a year-over-year increase of 3.02% [2]. - The sports rehabilitation segment saw a revenue increase of 40.76%, reaching 18.06 million yuan in 2024, supported by the sales growth of magnetic series products [2]. - The company is investing in R&D to develop innovative products, including a new generation of ultrasound diagnostic systems and radar magnetic stimulators, which are expected to enhance its market position [2].

证券研究报告 [Table_Title] 工业/安检收入增长 60%，打开成长新空间 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 康众医疗(688607) 投资评级 上次评级 | [Table_Author] 唐爱金 医药行业首席分析师 | | --- | | 执业编号：S1500523080002 | | 邮 箱：tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 新品放量+需求复苏，境内市场增长 48% 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B座 邮编：100031 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 ummary]2024 年年报和 2025 年一季报，2024 年实现营业收入 2.98 亿元（yoy+8.90%），归母净利润为 0.18 亿 ...

公司研究 [Table_ReportType] 公司点评报告 [安Ta琪bl酵e_母Sto(c6k0A0n2d9Ra8n)k] | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | 赵 雷 食品饮料行业分析师 执业编号：S1500524100003 邮 箱：zhaolei@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲 127 号 金隅大厦 B 座 邮编：100031 证券研究报告 [Table_Title] Q1 业绩亮眼，海外持续高增 风险因素：食品安全问题，行业竞争加剧 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 1 国内收入平稳，海外持续高增。分产品看，Q1 酵母及深加工产品、制 糖产品和包装类产品分别实现营收 27.73 亿元、1.57 亿元和 9500 万元， 同比分别+13.17%、-60.68%和-4.37%，食品原料实现营收 4.34 亿元。 分区域看，Q1 公司国内和国外分别录得营收 20.99 亿元和 16.84 亿元， 同比分别-0.3%和+22 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 鱼跃医疗(002223) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] "产品+营销"双轮驱动，塑造家用医疗 器械领先品牌 业务发展稳定势好，创新发展布局多 元领域 鱼跃医疗（002223）核心板块稳定增 长，电商渠道表现优异 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 血糖业务增长 40%，海外拓展成效凸显 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 umma ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 翔宇医疗(688626) 投资评级 点评： 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 1 上次评级 | 执业编号：S1500523080002 | | | --- | --- | | [Table_Author] 唐爱金 邮 | 医药行业首席分析师 箱：tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 营收增长亮眼，股权激励加码，成长可 期 营收实现快速增长，股权激励彰显成 长信心 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B座 邮编：100031 [Table_Title] 收入回归增长轨道，研发加码布局脑机 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 umma ...

公司基本情况 | 最新收盘价（元） | 25.33 | | --- | --- | | 总股本/流通股本（亿股）4.00 | / 4.00 | | 总市值/流通市值（亿元）101 | / 101 | | 52 周内最高/最低价 | 32.39 / 10.69 | | 资产负债率(%) | 15.0% | | 市盈率 | 180.93 | | 第一大股东 | 张家港灿勤企业管理有 | | 限公司 | | 证券研究报告：通信 | 公司点评报告 股票投资评级 买入 |维持 个股表现 2024-04 2024-07 2024-09 2024-12 2025-02 2025-04 -24% -8% 8% 24% 40% 56% 72% 88% 104% 120% 灿勤科技 通信 资料来源：聚源，中邮证券研究所 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 灿勤科技(688182) 加速成长 l 事件 4 月7 日，公司披露2024 年年度报告，2024 年公司实现营收 4.11 亿元，同比+11.09%；归母净利润 5,779.43 万元，同比 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 迪安诊断(300244) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 特检占比持续提升，数智化提升运营 能力 夯实产品能力，ICL 实现 17%稳健增长 特检业务快速增长，自产产品拿证加 速 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 业绩短期承压，检验业务呈现高质量发展 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 ummary] 2024 年年报，2024 年实现营业收入 121.96 亿元（yoy- 9.04%），归母 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on growth and market position [8]. Core Viewpoints - The company has demonstrated significant revenue growth in its 3D CAD segment, achieving a revenue of 242 million yuan in 2024, which represents a year-on-year increase of 29.21% [1]. - The company has made breakthroughs in three key technical dimensions: core stability, parametric stability, and large assembly design support capabilities [1]. - The company has successfully expanded its key account (KA) customer base and deepened channel cooperation with major clients in various sectors [1]. - The company has achieved notable success in overseas markets, with a main business revenue growth rate of 28.77% [1]. - The global industrial software market is projected to be approximately 520 billion USD in 2024, indicating substantial growth potential for the company [1]. Financial Summary - In 2024, the company reported total revenue of 888 million yuan, a year-on-year growth of 7.31%, and a net profit attributable to the parent company of 64 million yuan, reflecting a growth of 4.17% [2]. - The company's gross margin improved to 94.4% in 2024, while the sales expense ratio decreased by 5.96% [1]. - The earnings per share (EPS) for 2025 is projected to be 0.63 yuan, with corresponding price-to-earnings (P/E) ratios of 140.38, 121.21, and 105.44 for 2025, 2026, and 2027 respectively [2][3].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook on the company's performance and growth potential [1][3]. Core Viewpoints - The company has ended inventory destocking with significant localization effects and is experiencing high growth in overseas markets. However, domestic sales are impacted by medical industry regulations, leading to a slowdown in growth [3]. - In 2024, the company achieved a revenue of 1.509 billion yuan, a year-on-year increase of 8.76%, and a net profit of 219 million yuan, up 13.98% year-on-year. The first quarter of 2025 saw a revenue of 348 million yuan, reflecting a year-on-year growth of 12.6% [1][3]. - The company is expanding its market presence in Mexico, Europe, and emerging markets in South America and Southeast Asia, with foreign sales revenue reaching 797 million yuan, a year-on-year increase of 23.74%, accounting for 52.82% of total revenue [3]. - The company has shown strong growth in its anesthesia and urology product lines, with revenues of 477 million yuan and 216 million yuan, respectively, while nursing and catheter products also saw significant growth [3]. Financial Summary - The company’s revenue is projected to grow from 1.753 billion yuan in 2025 to 2.438 billion yuan in 2027, with year-on-year growth rates of 16.1%, 17.6%, and 18.2% respectively [4]. - The net profit attributable to the parent company is expected to increase from 264 million yuan in 2025 to 399 million yuan in 2027, with growth rates of 20.3%, 22.9%, and 23.1% [4]. - The gross margin for 2024 was reported at 44.53%, a decrease of 1.36 percentage points year-on-year, primarily due to the higher proportion of lower-margin overseas sales [3][4]. - The company has effectively controlled expenses, leading to an increase in the net profit margin to 15.14%, up 0.4 percentage points year-on-year [3].